You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

Investigational Drug Information for LNP023


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for LNP023?

LNP023 is an investigational drug.

There have been 20 clinical trials for LNP023. The most recent clinical trial was a Phase 2 trial, which was initiated on September 20th 2021.

The most common disease conditions in clinical trials are Hemoglobinuria, Hemoglobinuria, Paroxysmal, and Kidney Diseases. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There is one US patent protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for LNP023
TitleSponsorPhase
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSNovartis PharmaceuticalsPhase 3
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNNovartis PharmaceuticalsPhase 3
This is a Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.Novartis PharmaceuticalsPhase 3

See all LNP023 clinical trials

Clinical Trial Summary for LNP023

Top disease conditions for LNP023
Top clinical trial sponsors for LNP023

See all LNP023 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.